Investor's Business Daily
Medical Stock Hovers Near Buy Point After 46% Gain
📊
AI Sentiment
Positive
6/10
- Home
- NTRA
NTRA
Natera Inc.
as of 12-31-2025 3:03pm EST
$229.15
$0.83
-0.36%
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 27.0B | IPO Year: | 2015 |
| Target Price: | $238.20 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $125.38 - $246.90 | Next Earning Date: | 11-06-2025 |
| Revenue: | $2,116,676,000 | Revenue Growth: | 38.17% |
| Revenue Growth (this year): | 33.18% | Revenue Growth (next year): | 16.81% |
AI-Powered NTRA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 20 hours ago
AI Recommendation
hold
Model Accuracy: 74.19%
74.19%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Natera Inc. (NTRA)
Sheena Jonathan
Sell
Director, Other
NTRA Dec 19, 2025
Avg Cost/Share
$225.58
Shares
1,500
Total Value
$338,913.78
Owned After
22,532
Sheena Jonathan
Sell
Director, Other
NTRA Dec 17, 2025
Avg Cost/Share
$227.42
Shares
3,070
Total Value
$696,912.17
Owned After
22,532
Moshkevich Solomon
Sell
PRESIDENT, CLINICALDIAGNOSTICS
NTRA Dec 12, 2025
Avg Cost/Share
$230.76
Shares
4,692
Total Value
$1,082,714.19
Owned After
113,065
SEC Form 4
ROSENMAN HERM
Sell
Director
NTRA Dec 12, 2025
Avg Cost/Share
$227.89
Shares
48,419
Total Value
$11,011,477.42
Owned After
20,342
Chapman Rowan E
Sell
Director
NTRA Dec 5, 2025
Avg Cost/Share
$243.23
Shares
4,366
Total Value
$1,061,389.14
Owned After
6,143
Moshkevich Solomon
Sell
PRESIDENT, CLINICALDIAGNOSTICS
NTRA Dec 1, 2025
Avg Cost/Share
$238.19
Shares
3,000
Total Value
$714,458.77
Owned After
113,065
Chapman Steven Leonard
Sell
CEO AND PRESIDENT
NTRA Dec 1, 2025
Avg Cost/Share
$238.20
Shares
4,400
Total Value
$1,047,501.95
Owned After
141,372
BOTHA ROELOF
Sell
Director
NTRA Nov 24, 2025
Avg Cost/Share
$234.43
Shares
75,000
Total Value
$17,708,935.58
Owned After
1,154,198
Sheena Jonathan
Sell
Director, Other
NTRA Nov 11, 2025
Avg Cost/Share
$208.03
Shares
1,500
Total Value
$311,933.77
Owned After
22,532
Sheena Jonathan
Sell
Director, Other
NTRA Nov 7, 2025
Avg Cost/Share
$194.12
Shares
3,070
Total Value
$591,159.28
Owned After
22,532
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Sheena Jonathan | NTRA | Director, Other | Dec 19, 2025 | Sell | $225.58 | 1,500 | $338,913.78 | 22,532 | |
| Sheena Jonathan | NTRA | Director, Other | Dec 17, 2025 | Sell | $227.42 | 3,070 | $696,912.17 | 22,532 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Dec 12, 2025 | Sell | $230.76 | 4,692 | $1,082,714.19 | 113,065 | |
| ROSENMAN HERM | NTRA | Director | Dec 12, 2025 | Sell | $227.89 | 48,419 | $11,011,477.42 | 20,342 | |
| Chapman Rowan E | NTRA | Director | Dec 5, 2025 | Sell | $243.23 | 4,366 | $1,061,389.14 | 6,143 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Dec 1, 2025 | Sell | $238.19 | 3,000 | $714,458.77 | 113,065 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Dec 1, 2025 | Sell | $238.20 | 4,400 | $1,047,501.95 | 141,372 | |
| BOTHA ROELOF | NTRA | Director | Nov 24, 2025 | Sell | $234.43 | 75,000 | $17,708,935.58 | 1,154,198 | |
| Sheena Jonathan | NTRA | Director, Other | Nov 11, 2025 | Sell | $208.03 | 1,500 | $311,933.77 | 22,532 | |
| Sheena Jonathan | NTRA | Director, Other | Nov 7, 2025 | Sell | $194.12 | 3,070 | $591,159.28 | 22,532 |
Latest Natera Inc. News
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
Investor's Business Daily
Medical Stocks On The Move In Top Growth List As Health Sector Performance Brightens
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Is Natera’s 486% Three Year Surge Still Justified by Its Fundamentals?
📊
AI Sentiment
Positive
6/10
Compare NTRA vs Leading Stocks
See how NTRA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.